Related conditions

New and developing therapies for AL amyloidosis. Zumbo G et al. Expert Opin Pharmacother. 2016 Dec 29:1-11. doi: 10.1080/14656566.2016.1274971. [Epub ahead of print]. Pathological characteristics of fifty patients with renal amyloidosis in Sri Lanka Dasanayaka DL et al. Ceylon Med J. 2016 Dec 30;61(4):189-190. doi: 10.4038/cmj.v61i4.8388. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and…


Emerging treatments

Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Vogl DT et al. Clin Cancer Res. 2017 Jan 4. pii: clincanres.2526.2016. doi: 10.1158/1078-0432.CCR-16-2526. [Epub ahead of print]. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Jan 16. doi: 10.1080/13543776.2017.1282945.…


Biology and genetics

Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Durusu İZ et al. Leuk Res. 2017 Jan 16;55:33-40. doi: 10.1016/j.leukres.2017.01.019. [Epub ahead of print]. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J et al. Mol Cancer Res. 2017 Jan 23. pii: molcanres.0242.2016. doi: 10.1158/1541-7786.MCR-16-0242-T. [Epub ahead of print].…



Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Kapoor P et al. Nat Rev Clin Oncol. 2017 Feb;14(2):73-74. doi: 10.1038/nrclinonc.2016.221. Epub 2017 Jan 10. Trends in overall survival and costs of multiple myeloma, 2000-2014. Fonseca R et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print]. Current treatment options of T cell-associated immunotherapy in multiple myeloma. Liu H et…


Supportive treatments

Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M et al. Expert Rev Hematol. 2017 Jan 17. doi: 10.1080/17474086.2017.1283213. [Epub ahead of print].

Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma.
Audat ZA et al. Scoliosis Spinal Disord. 2016 Dec 29;11:47. doi: 10.1186/s13013-016-0107-6. eCollection 2016.


Complications of myeloma and its treatments

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Snowden JA et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14514. [Epub ahead of print]. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Beijers AJ et al. Ann Hematol. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead…


Current treatments

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BG et al. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. doi: 10.1016/S0140-6736(16)31594-X. [Epub ahead of print]. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly…


Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.

Snowden et al. (2017) British Journal of Haematology